p53 regulates mitochondrial function and alpha-synuclein aggregation in Parkinson's disease.

Area of Science:

• Neuroscience
• Molecular Biology
• Cell Biology

Background:

• Parkinson's disease (PD) involves mitochondrial dysfunction and alpha-synuclein (α-syn) aggregation.
• The tumor suppressor p53's role in PD pathology is emerging but not fully understood.
• The precise mechanisms linking p53 to mitochondrial health and α-syn pathology in PD require elucidation.

Purpose of the Study:

• To investigate the role of p53 in regulating mitochondrial function and α-syn aggregation in Parkinson's disease.
• To explore the therapeutic potential of p53 inhibition in PD models.

Main Methods:

• Utilized an MPTP-induced mouse model of Parkinson's disease.
• Conducted cellular experiments involving p53 inhibition with pifithrin-α.
• Performed in vitro studies to assess p53 and α-syn interactions.

Main Results:

• Elevated p53 and α-syn expression and mitochondrial impairment were observed in PD models.
• p53 inhibition improved mitochondrial function via mitophagy and dynamics, reducing oxidative stress and apoptosis.
• p53 directly interacted with α-syn, accelerating its phase separation and fibril formation.

Conclusions:

• p53 plays a critical role in modulating mitochondrial function and promoting pathogenic α-syn aggregation in Parkinson's disease.
• Targeting p53 represents a potential therapeutic avenue for mitigating neurodegeneration in PD.